Clinical Trial: Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

Study Status: Enrolling by invitation
Recruit Status: Enrolling by invitation
Study Type: Interventional

Official Title: A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (Same as current

Current Secondary Outcome:

  • Change from Baseline in serum FGF23 [ Time Frame: 72 Weeks ]
  • Change from Baseline in serum ALP [ Time Frame: 72 Weeks ]
  • Change from Baseline in serum 1,25(OH)2D [ Time Frame: 72 Weeks ]
  • Change from Baseline in serum iPTH [ Time Frame: 72 Weeks ]
  • Change from Baseline in serum and urine phosphorus [ Time Frame: 72 Weeks ]
  • Change from Baseline in serum TRP and TMP/GFR [ Time Frame: 72 Weeks ]
  • Change from Baseline in serum BALP [ Time Frame: 72 Weeks ]
  • Change from Baseline in serum CTx [ Time Frame: 72 Weeks ]
  • Change from Baseline in serum P1NP [ Time Frame: 72 Weeks ]


Original Secondary Outcome: Same as current

Information By: Ultragenyx Pharmaceutical Inc

Dates:
Date Received: December 3, 2014
Date Started: December 2014
Date Completion: August 16, 2018
Last Updated: May 2, 2017
Last Verified: May 2017